Muehlenkreiskliniken AöR — Clinical Trial Site

50 Registered trials

29 Currently recruiting

Organisation

Muehlenkreiskliniken AöR

Location

Minden, Germany

Identifier

ORG-100039347

Address

Hans-Nolte-Strasse 1, Haeverstaedt, 32429, Germany

Departments

#2507: Universitätsklinik für Hämatologie, Onkolologie, Gerinnungsstörungen und Palliativmedizin
#7215;Klinik fuer Dermatologie HautTumorCentrum
127607: Universitätsklinik für Hämatologie/ Onkologie/ Hämostaseologie und Palliativmedizin
306: Universitätsklinik für Dermatologie, Allergologie
9196: Klinik fuer Dermatologie HautTumorCentrum
Brustzentrum Minden-Herford
Clinic for hematology, oncology, hemostaseology and palliative medicine
Department of Dermatology, Venereology, Allergology and Phlebology
Department of Hematology, Oncology and paliative care
Department of hematology/oncology/palliative care
Department of Neurology und Neurogeriatrics
Dermatology, allergology and venerology
Dermatology, Venerology, Allergology and Phlebology
Hämatologie/Onkologie, Hämostaseologie und Palliativmedizin
Haut-Tumor-Zentrum
Hematology
Johannes Wesling Klinikum Klinik für Rheumatologie und klinische Immunologie
Johannes Wesling Klinikum Minden
Johannes Wesling Klinikum Minden Universitätsklinik für Hämatologie/Onkologie
Johannes Wesling Klinikum Minden,Klinik f. Haematologie, Onkologie u. Palliativmedizin
Johannes Wesling Klinikum-Klinik für Rheumatologie und klinische Immunologie
Johannes-Wesling-Klinikum Minden Universitätsklinik für Neurologie und Neurogeriatrie
Klinik f. Haematologie, Onkologie und Palliativmedizin
Klinik für Hämatologie
Klinik für Hämatologie und Onkologie
Klinik für Hämatologie, Onkologie Hämosaseologie und Palliativmedizin
Klinik für Hämatologie, Onkologie und Palliativmedizin
Klinik für Hämatologie/Onkologie, Hämostaseologie und Palliativmedizin
Klinik für Kinder- und Jugendmedizin Päd. Hämatologie / Onkologie Station E 22
Muhlenkreiskliniken AöR
Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie Onkologie u Palliativmed
Onkologie, Gerinnungsstörungen und Palliativmedizin
Onkologie, Gerinnunsgsstoerungen und Palliativmedizin
Päd. Hämatologie / Onkologie
Universitaetsklinik fuer Haematologie, Onkologie, Gerinnungsstoerungen und Palliativmedizin
Universitätsklinik für Dermatologie, Venerologie, Allergologie und Phlebologie
Universitätsklinik für Dermatologie, Venerologie, Allergologie, Phlebologie - HautTumorZentrum
Universitätsklinik für Hämatologie, Onkologie, Hämostaseologie und Palliativmedizin
Universitätsklinik für Kinder- und Jugendmedizin
Universitätsklinik für Neurologie und Neurogeriatrie
University hospital of hematology/oncology/palliative care
Zentrum für Innere Medizin

Clinical trials at this site (50)

Search interface

A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting

2023-503219-14-01 systemic sclerosis associated interstitial lung disease 10 2024-05-22
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap… Recruiting

2022-502889-24-00 chemotherapy-induced polyneuropathy (CIPN) 5 2024-02-13
Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting

2022-502732-39-00 Previously treated non-ocular advanced melanoma 10 2023-09-01
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting

2023-508101-24-00 Lymphoblastic lymphoma 5 2019-08-01
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513266-19-00 Hidradenitis Suppurativa (HS) 5 2025-06-13
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended

2023-503652-27-00 Melanoma 5 2023-10-06
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in … Ended

2024-514945-12-00 locally advanced resectable adenocarcinoma of the oesop 10 2018-09-03
AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended

2023-509856-32-00 acute lymphoblastic leukemia in children and adolescent 5 2018-07-15
International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended

2024-515499-12-00 Acute lymphoblastic leukemia 5 2017-10-02
B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended

2023-505509-18-00 mature aggressive B-cell lymphoma and leukemia in child 5 2017-07-12
Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEA… Ended

2024-515619-23-00 essential thrombocythemia 4 2015-06-29
Clinical trial of MK-7648A in adults and children with skin cancer Ended

2022-501417-31-01 melanoma 5 2023-08-01
Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended

2024-519227-22-00 Myeloproliferative neoplasm in accelerated phase (MPN-A 9 2022-11-03
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended

2024-511996-13-00 Previously untreated, unresectable, or metastatic melan 5 2022-05-11